Instrument Inactif

Communiqués Antibe Therapeutics Inc.

Actions

ATE

CA0370255097

Recherche biotechnologique et médicale

Communiqués

04/07/24	Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”)	PU
24/04/24	Antibe Announces Appointment of Receiver	BU
22/04/24	ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS	AQ
19/04/24	Antibe Provides Update on CCAA Proceedings	BU
16/04/24	Antibe Announces TSX Delisting Review	BU
10/04/24	ANTIBE TO FILE AN APPLICATION FOR AN INITIAL ORDER UNDER COMPANIES CREDITORS ARRANGEMENT ACT	AQ
10/04/24	Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act	BU
09/04/24	DELETED: Canadian Investment Regulatory Organization Trade Resumption - ATE	AQ
09/04/24	Canadian Investment Regulatory Organization Trading Halt - ATE	AQ
09/04/24	Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act	BU
01/04/24	Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	BU
20/03/24	Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting	BU
07/03/24	Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting	BU
04/03/24	Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma	BU
14/02/24	Antibe Reports Q3 2024 Interim Financial and Operating Results	BU
01/02/24	Antibe Extends Early Warrant Exercise Incentive Program	BU
29/12/23	Antibe Announces Early Warrant Exercise Incentive Program	BU
12/12/23	Antibe Therapeutics Announces Amendment to Warrant Terms	BU
13/11/23	Antibe Reports Q2 2024 Interim Financial and Operating Results	BU
09/11/23	Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation	BU
02/11/23	ANTIBE COMPLETES FIRST CLINICAL STUDY OF OTENAPROXESUL'S NEW FORMULATION	AQ
01/11/23	Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation	BU
19/10/23	Antibe Initiates First Clinical Study of Otenaproxesul's New Formulation	AQ
18/10/23	Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation	BU
28/09/23	Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul	BU